Whalesbook
So, Global Health jiske under Medanta chalta hai, unke Q4FY26 ke results ne sabko khush kar diya. Company ka revenue 25% jump karke ₹1,159 Crore ho gaya. Aur profit after tax toh 42% bhag kar ₹144 Crore pahunch gaya! Isse unki profit margin 12.4% ho gayi hai. Operating EBITDA bhi ₹244 Crore raha, matlab 21.0% ki margin. Yeh sab numbers acche operational trends dikha rahe hain.
Bade Plans Aur Noida Hospital Ka Game
Abhi jo hospitals chal rahe hain, unmein company lagbhag 500 naye beds add karne wali hai. Aur future ke liye toh plan bahut bada hai – next 3-4 saal mein 2,700 naye beds add karne ka target hai 5 naye greenfield projects mein. Noida wala naya hospital bhi ab thoda track par aa raha hai. Uske EBITDA losses kam ho kar ₹23.6 Crore ho gaye hain (pehle ₹32.0 Crore the), matlab progress toh hai. Management ko umeed hai ki yeh facility FY27 ke second half tak breakeven kar legi, jo bahut badi baat hogi.
Company ke paas cash bhi accha hai, FY26 ke end mein ₹590 Crore net cash aur ₹714 Crore operating cash flow tha.
Competition Aur Valuation Ka Scene
Indian healthcare sector mein Medanta 12-15% CAGR growth expect kar raha hai, kyunki logon ko ab health par kharch karne ka trend badh raha hai. Lekin market mein competition bhi kam nahi hai. Apollo Hospitals (Market Cap ~₹75,000 Cr), Max Healthcare (Market Cap ~₹38,000 Cr), aur Fortis Healthcare (Market Cap ~₹27,000 Cr) jaise bade players bhi apna business badha rahe hain. Medanta ka valuation abhi FY28 ke future earnings ke hisab se 23 times EV/EBITDA ke aas paas hai, jo competitors ke comparison mein theek lag raha hai.
Kahan Hai Asli Risk?
Ab aata hai risk wala part. Itne bade expansion plan, matlab 2,700 naye beds, mein paisa toh bahut lagega aur execution bhi accha hona chahiye. Agar projects late ho gaye ya Noida hospital jaisa koi bhi facility expect ke hisab se nahi chala, toh sab gadbad ho sakta hai. Noida mein abhi occupancy sirf 30% hai, aur agar H2FY27 tak breakeven nahi hua toh yeh ek bada setback hoga. Industry mein regulatory changes aur skilled logon ke liye badhti competition bhi ek risk hai.
FY27 Ka Outlook
FY27 ke liye Medanta ko Noida hospital ke breakeven, existing facilities mein beds badhane, aur international business se growth ki ummeed hai. Company FY27 mein ₹800-900 Crore capital expenditure karne ka plan bana rahi hai, matlab investment jaari rahegi. Woh inorganic acquisition ke liye bhi open hain agar koi achha deal miley toh. Analysts ka kehna hai ki agar sab plans successfully execute hue toh earnings grow hoti rahegi.